ABOUT US
TECHNOLOGY
PIPELINE
PARTNERSHIP
MEDIA
RECRUITMENT
CONTACT
EN
EN

EMPOWERING NEXT GENERATION BIOCONJUGATE
THERAPEUTICS WITH REVOLUTIONARY
CONJUGATION TECHNOLOGIES

Scroll down

TECHNOLOGY

iLDC TECHNOLOGY
The iLDC technology employs an immobilized engineered transpeptidase to enable precise and efficient attachment of payloads to specific site of antibodies.
iGDC TECHNOLOGY
The iGDC platform utilizes an immobilized engineered glycotransferase to enable precise and efficient attachment of payloads to specific site of antibodies.
Learn more
PIPELINE

We are commited to develop differentiated next generation bioconjugate therapeutics through leveraging proprietary bioconjugation platform and integrating with other cutting-edge technologies, fulfilling urgent unmet needs.[More]

Partnership
NEWS
GeneQuantum Healthcare joins Johnson & Johnson Innovation JLABS @ Shanghai becoming its 100th resident company

GeneQuantum Healthcare joins Johnson & Johnson Innovation JLABS @ Shanghai becoming its 100th resident company
WCLC 2024: The latest research results of the new generation HER2 ADC GQ1005 are unveiled

WCLC 2024: The latest research results of the new generation HER2 ADC GQ1005 are unveiled

14.09 2024
Forge Stronger Partnership for Advanced ADC Development! GeneQuantum Healthcare and Aimed Bio collaborate to develop five innovative ADC drugs

Forge Stronger Partnership for Advanced ADC Development! GeneQuantum Healthcare and Aimed Bio collaborate to develop five innovative ADC drugs

06.07 2023
all news
ABOUT US
INNOVATIVE ECOSYSTEM BUILDER IN THE FIELD OF BIOCONJUGATE THERAPEUTICS
To drive impactful advances in global healthcare through pioneering and disruptive site-specific bioconjugation technologies that empower the next generation ADC discovery and development
To revolutionize the existing ADC therapy by significantly enhancing efficacy and safety
Learn more